Next-Generation Biomanufacturing Market Current Scenario with Future Trends Analysis to 2031

Next-Generation Biomanufacturing Market worth $43.16 Billion by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Next-Generation Biomanufacturing Market (Medical Applications (Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, And Other Applications), Products (Continuous Upstream Biomanufacturing Products, Single-Use Upstream Biomanufacturing Products, And Downstream Biomanufacturing Products), Workflow (Upstream And Downstream Biomanufacturing), End-User (Biopharmaceutical Companies, CMOs (Contract Manufacturing Organizations)/CDMOS (Contract Development And Manufacturing Organization), And Research Institutions))- Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

The global next-generation biomanufacturing industry is projected to grow at a compound annual growth rate (CAGR) of 9.3% from 2022 to 2030, from an estimated valueof US$ 19.85 billion in 2021 to US$ 43.16 billion by 2030, according to the most recent research by InsightAce Analytic.

Get Free Access to Demo Report, Excel Pivot and ToC: www.insightaceanalytic.com/request-sample/1261

Compared to first-generation biomanufacturing products, next-generation biomanufacturing services enable the development and production of a greater variety of products with the best quality. These services concentrate on single-use technologies that improve process flexibility and efficiency, such as single-use bioreactors and bio-containers.
The market is expected to grow significantly during the forecast years due to factors such as advanced medical technologies, high demand for gene and cell therapy products, government initiatives to build more efficient next-generation bioprocessing units, high prevalence of genetic and chronic diseases, an aging population , growing public awareness of the advantages of next-generation bio-manufacturing, and the availability of established healthcare infrastructures. Drug and material discovery and production involves intricate processes and call for specialized machinery. The production of next-generation biomanufacturing products is anticipated to expand in the future years as a result of biopharmaceutical businesses using advanced biomanufacturing solutions to address these challenges and improve production quality and efficiency.
On the other hand, over the forecast period,the market adoption may be constrained by elements like the complexity of the process operations andthe shortage of qualified personnel.
Due to the region's highly developed biopharmaceutical industries, rapid adoption of contemporary technologies, and growing use of cutting-edge technologies, North America is anticipated to dominate the next-generation biomanufacturing market during the forecast period (2022-2030).

Expert Knowledge, Just a Click https://calendly.com/insightaceanalytic/30min?month=2025-04

Key market players operating in the next-generation biomanufacturing market include Applikon Biotechnology BV (Netherlands), bbi-biotech GmbH (Germany), Danaher Corporation (US), Eppendorf AG (Germany), Esco Group of Companies (US), GEA Group Aktiengesellschaft (Germany), Meissner Filtration Products, Inc. (US), Merck KGaA (Germany), PBS Biotech, Inc. (US), Pierre Guérin (France), Sartorius AG (Germany), Shanghai Bailun Biotechnology Co. Ltd. (China), Solaris Biotechnology Srl. (Italy), Thermo Fisher Scientific Inc. (US), ZETA GmbH (Austria), among others.
Key developments in the market:
• In August 2021, PBS Biotech (US) secured its highest funding round with BroadOak Capital Partners to grow its product offerings and capabilities. The budget is used to expand PBS's product offerings and abilities and meet the demand for cell therapies.
• In February 2021, Merck (Germany) partnered with Alteogen, Inc. (South Korea), a company providing late-stage CDMO services through Merck's BioReliance end-to-end solutions. Alteogen selected Merck to develop and produce recombinant biologics for developing and clinically evaluating next-generation therapeutics of monoclonal antibody drugs.
• In November 2020, Merck (Germany) collaborated with Transcenta, a biotherapeutics company, to implement & advance continuous manufacturing for protein therapeutics.

Unlock Your GTM Strategy: www.insightaceanalytic.com/customisation/1261

Market Segments

Next-Generation Biomanufacturing Market, by Medical Applications, 2022-2030(Value US$ Bn)
• Monoclonal Antibodies
• Hormones
• Vaccines
• Recombinant Proteins
• Other Applications

Next-Generation Biomanufacturing Market, by Products, 2022-2030(Value US$ Bn)
• Continuous Upstream Biomanufacturing Products
• Single-Use Upstream Biomanufacturing Products
• Downstream Biomanufacturing Products

Next-Generation Biomanufacturing Market, by Workflow, 2022-2030(Value US$ Bn)
• Upstream Biomanufacturing
• Downstream Biomanufacturing

Next-Generation Biomanufacturing Market, by End-Users, 2022-2030(Value US$ Bn)
• Biopharmaceutical Companies
• CMOs (Contract manufacturing organizations)/CDMOs (Contract Development and Manufacturing Organization)
• Research Institutions

Next-Generation Biomanufacturing Market, by Region, 2022-2030(Value US$ Bn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Next-Generation Biomanufacturing Market, by Country, 2022-2030(Value US$ Bn)
• U.S.
• Canada
Europe Next-Generation Biomanufacturing Market, by Country, 2022-2030(Value US$ Bn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Next-Generation Biomanufacturing Market, by Country, 2022-2030(Value US$ Bn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Next-Generation Biomanufacturing Market, by Country, 2022-2030(Value US$ Bn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Next-Generation Biomanufacturing Market, by Country, 2022-2030(Value US$ Bn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com
r4e4
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.